This is a non-randomized phase II trial of denosumab at 120 mg subcutaneous injection monthly
in pre- and post-menopausal women diagnosed with stage 0-III breast cancer who are currently
not receiving anticancer treatment with hormonal therapies, chemotherapy, or radiation. All
patients will undergo quantification of breast density by MRI at baseline and after 6 months
on denosumab. Because the therapeutic agent is an injectable drug, the investigators will
conduct a single arm study with both pre- and post-treatment measurements to determine the
extent of variability in breast density over time and a placebo treatment period or group
will not be utilized. This is an investigator initiated trial and Amgen (SPONSOR) will
provide the trial drug denosumab.